Royal Bank of Canada reaffirmed their outperform rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report published on Wednesday morning,Benzinga reports. They currently have a ...

The FDA approved an oral combination of meloxicam and rizatriptan (Symbravo) to treat adults with acute migraine with or ...

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.

Analyst Ami Fadia of Needham maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), retaining the price target of ...

The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's non-opioid treatment Journavx.

This news article is based on a press release statement from Axsome Therapeutics (NASDAQ:AXSM). The company continues to focus on addressing critical gaps in CNS treatment and advancing patient ...

Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor ...

CNS-focused biopharma Axsome Therapeutics has won US Food and Drug Administration (FDA) approval for Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in ...

Analyst Vikram Purohit of Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), retaining the price target of ...

Symbravo, for the acute treatment of migraine with or without aura in adult patients, showed superior efficacy across a broad range of severity, Axsome said Thursday. A single oral dose gave patients ...